Zheng Wei, Ph.D., Co-founder, CEO

Dr. Zheng Wei has been serving as our CEO since he co-founded the company in 2012. He has over 20 years of biopharmaceutical industry experience in the autoimmune diseases and inflammation therapeutic areas.

Prior to co-founding Connect, Dr. Zheng was Director of Immunology at Arena Pharmaceuticals where he oversaw its immunology discovery programs. Prior to serving at Arena, Dr. Zheng was a founding scientist at ChemoCentryx. During his 10-year tenure at ChemoCentryx, he led the implementation of the company's proprietary technology platform, and the discovery of drug candidates that entered Phase II and Phase III clinical trials for autoimmune disease indications including Crohn's disease. His discovery research contributed significantly to the landmark strategic alliance between the company and GSK. Prior to joining ChemoCentryx, Dr. Zheng was a scientist at Glycomed (acquired by Ligand Pharmaceuticals). He also conducted research on human antibody at Stanford University School of Medicine. 

Dr. Zheng is an inventor of 16 issued patents and several pending patent applications on immunology related therapeutic agents and technologies. He received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis. He has been selected to the National 1000Talents Plan of China.

William (Wubin) Pan, Ph.D., Co-founder, President and Chairman of the Board

Dr. Pan is a co-founder of Connect and has been serving as our President and Chairman of the Board of Directors. He has over 20 years of experiences in biopharmaceutical R&D including 10 years in Europe and North America.

Prior to co-founding Connect, Dr. Pan co-founded Crown Bioscience Inc., a US venture-backed US company with major operations in China (Beijing & Shanghai) providing CRO services to international biopharmaceutical companies. He has served at various executive leadership positions at the company, including China President, Chief Operation Officer, and Executive Vice President. While there, Dr. Pan made seminal contributions to the company's growth into a global leader in translational oncology drug development services. (The company went IPO in 2017 and was later acquired for $400 million by JSR of Japan.)

Prior to Crown Bioscience, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd. (Shenzhen, China) after he returned to China as an entrepreneur in 2000. Between 2001 and 2006, he co-founded and served as Vice President and/or General Manager for two other biotech companies, where he played key roles for the development of several gene-based therapeutic biologics. He was involved in the development and successful marketing of several biomedical products.

Dr. Pan obtained his Ph.D. in Biology in Sussex University (UK) and postdoctoral training at University of California at Berkeley. He holds an MBA from Tsing-Hua University.


TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: 10th Floor, XiangTang Development Building #3 ChaoYang Dong Road, Taicang,Jiangsu Province, China ,215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower